Kelly Boothe
Contacto de Relaciones con Inversores en Carmot Therapeutics, Inc. .
Cargos activos de Kelly Boothe
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
Carmot Therapeutics, Inc.
 Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | Contacto de Relaciones con Inversores | - | - |
| Public Communications Contact | - | - |
Historial de carrera de Kelly Boothe
Antiguos cargos conocidos de Kelly Boothe.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| SPYRE THERAPEUTICS, INC. | Contacto de Relaciones con Inversores | - | - |
| Public Communications Contact | - | - |
Estadísticas
Internacional
| Estados Unidos | 3 |
Operativa
| Investor Relations Contact | 2 |
| Public Communications Contact | 2 |
Sectorial
| Health Technology | 3 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| SPYRE THERAPEUTICS, INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | Health Technology |
- Bolsa de valores
- Insiders
- Kelly Boothe
- Experiencia
